Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Net Income: 2017-2025

Historic Net Income for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$83.2 million.

  • Cidara Therapeutics' Net Income fell 18396.22% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.4 million, marking a year-over-year decrease of 2564.97%. This contributed to the annual value of $464,000 for FY2024, which is 78.41% down from last year.
  • According to the latest figures from Q3 2025, Cidara Therapeutics' Net Income is -$83.2 million, which was down 223.64% from -$25.7 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Net Income ranged from a high of $14.2 million in Q3 2022 and a low of -$83.2 million during Q3 2025.
  • In the last 3 years, Cidara Therapeutics' Net Income had a median value of -$450,000 in 2024 and averaged -$10.8 million.
  • In the last 5 years, Cidara Therapeutics' Net Income surged by 178.78% in 2022 and then crashed by 18,396.22% in 2025.
  • Cidara Therapeutics' Net Income (Quarterly) stood at -$16.8 million in 2021, then grew by 19.08% to -$13.6 million in 2022, then skyrocketed by 136.54% to $5.0 million in 2023, then slumped by 98.75% to $62,000 in 2024, then tumbled by 18,396.22% to -$83.2 million in 2025.
  • Its Net Income was -$83.2 million in Q3 2025, compared to -$25.7 million in Q2 2025 and -$23.5 million in Q1 2025.